Pregled bibliografske jedinice broj: 1051441
Nonalcoholic fatty liver disease as a risk factor for Clostridioides difficile infection
Nonalcoholic fatty liver disease as a risk factor for Clostridioides difficile infection // European journal of clinical microbiology & infectious diseases, 39 (2020), 3; 569-574 doi:10.1007/s10096-019-03759-w (međunarodna recenzija, članak, znanstveni)
CROSBI ID: 1051441 Za ispravke kontaktirajte CROSBI podršku putem web obrasca
Naslov
Nonalcoholic fatty liver disease as a risk factor
for Clostridioides difficile infection
Autori
Papić, Neven ; Jelovčić, Fabijan ; Karlović, Marko ; Stemberger Marić, Lorna ; Vince, Adriana
Izvornik
European journal of clinical microbiology & infectious diseases (0934-9723) 39
(2020), 3;
569-574
Vrsta, podvrsta i kategorija rada
Radovi u časopisima, članak, znanstveni
Ključne riječi
Clostridioides difficile ; Healthcare-associated diarrhea ; NAFL D ; NASH ; Nosocomial infections
Sažetak
Clostridioides difficile infection (CDI) is the leading cause of healthcare-associated diarrhea while nonalcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver disease. The aim of this study was to determine whether NAFLD increases susceptibility to CDI. A retrospective cohort study included patients ≥ 65 years, treated with antimicrobial therapy ≥ 24 h, and hospitalized ≥ 72 h in a 36-month period. Three-hundred fourteen patients were included ; 83 with NAFLD and 231 controls. Except for diabetes mellitus (37.35% vs. 25.11%, p = 0.0462) and obesity (18.07% vs. 8.23%, p = 0.0218) that were more frequent in NAFLD group, there were no differences in other comorbidities, hospital admissions, antibiotic therapy within 3 months, prescription, and duration of antibiotic therapy. Fourteen (16.9%) patients with NAFLD and 17 (7.4%) in control group developed in-hospital CDI (p = 0.0156). The Charlson Age-Comorbidity Index > 6 (OR 4.34, 95%CI 1.39-13.57), hospital admission within 3 months (OR 7.14, 95%CI 2.33-21.83), serum albumins < 28 g/L (OR 3.15, 95%CI 1.04- 9.53), NAFLD (OR 3.27, 95%CI 1.04-10.35), eGFR < 40 (OR 4.89, 95%CI 1.61-14.88), treatment with piperacillin/tazobactam (OR 4.86, 95%CI 1.59- 14.83), and carbapenems (OR 3.99, 95%CI 1.28- 12.40) were independently associated with CDI. Our study identified NAFLD as an independent predictor of CDI.
Izvorni jezik
Engleski
Znanstvena područja
Kliničke medicinske znanosti
POVEZANOST RADA
Ustanove:
Stomatološki fakultet, Zagreb,
Medicinski fakultet, Zagreb,
Klinika za infektivne bolesti "Dr Fran Mihaljević"
Citiraj ovu publikaciju:
Časopis indeksira:
- Current Contents Connect (CCC)
- Web of Science Core Collection (WoSCC)
- Science Citation Index Expanded (SCI-EXP)
- SCI-EXP, SSCI i/ili A&HCI
- Scopus
- MEDLINE